Vapotherm
Vapotherm offers high velocity therapy, a non-invasive respiratory support technology beneficial for mask-intolerant patients, and provides products like the HVT 2.0 and Precision Flow systems used in over 40 countries and trusted by more than 2,400 hospitals worldwide.
Services
Vapotherm offers high velocity therapy, a non-invasive respiratory support technology. This service provides mask-free respiratory support, which benefits patients who are mask-intolerant. High velocity therapy serves as an alternative to traditional non-invasive positive pressure ventilation (NiPPV) and is used for treating undifferentiated respiratory distress. The company also provides extensive educational resources, including blogs, case studies, and clinical research. Vapotherm's services are available in more than 40 countries and are trusted by over 2,400 hospitals worldwide.
Products
Vapotherm's key products include the HVT 2.0 system and the Precision Flow system. The HVT 2.0 system is designed for both pediatric and adult patients, and it includes disposable accessories for ease of use. The Precision Flow Hi-VNI system is specifically used for neonatal patients and offers both capital and disposable accessories. Additionally, Vapotherm's products are designed to provide heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. The products are supported by a global installed base of over 37,000 capital units.
History
Vapotherm has been innovating in the non-invasive respiratory support category for more than 20 years. The company's high velocity therapy is backed by a substantial body of research and randomized controlled trials. Throughout its history, Vapotherm has treated over 4.1 million patients and has continuously expanded its market presence to more than 40 countries. Vapotherm's innovation and dedication to respiratory care have led to its products being widely adopted by over 2,400 hospitals.
Sector
Vapotherm operates within the medical device and healthcare technology sector, focusing specifically on non-invasive respiratory support systems. The company's high velocity therapy is utilized in various patient care areas, including emergency rooms, adult critical care, pediatric care, and neonatal units. Vapotherm also supports independent clinical research through its dedicated Investigator Initiated Research Program, which aims to further the development and understanding of non-invasive respiratory therapies.
Global Reach
Vapotherm's high velocity therapy is available in more than 40 countries worldwide. The company's products are used in over 2,400 hospitals globally, treating a diverse patient population. Vapotherm has a global installed base of over 37,000 capital units and offers a trial program for its HVT 2.0 system to assess its suitability for various patient cases. The company continues to expand its international footprint, driven by a commitment to improving respiratory care across different healthcare settings.